Key points are not available for this paper at this time.
Recently published data identified cancer patients with bone metastases receiving continuous monthly antiresorptive drugs (bisphosphonates and/or denosumab) as patients at high risk for Medication-Related Osteonecrosis of the Jaw (MRONJ), even with late onset. A retrospective multicenter study was conducted between 2000 and 2020 at all breast centers across Tyrol (Austria), screening all patients with breast cancer and bone metastases receiving antiresorptive therapy. The MRONJ incidence was found to be considerably high in patients receiving denosumab (11.6%-16.3%), with an elevated cumulative incidence at 6 years. This commentary underlines some important results of the study and proposes further evaluation of the group of patients receiving a sequence of bisphosphonates and denosumab. Furthermore, other interesting data could come from patients treated in the last decade, receiving more effective anticancer treatments but also more frequently denosumab, in comparison with patients treated in previous years.
Fusco et al. (Mon,) studied this question.